Skip to main content

Table 2 Changes in clinical data of diabetes mellitus complicated by chronic liver injury (NAFLD and ALD)

From: Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

 

NAFLD group (n = 62)

 

ALD group (n = 17)

Pre-treatment

Post-treatment

P value

Pre-treatment

Post-treatment

P value

HbA1c (%)

8.57 ± 1.23

7.99 ± 1.22

<0.001

HbA1c (%)

8.29 ± 1.77

7.79 ± 1.42

0.099

AST (IU/L)

52.7 ± 25.3

55.5 ± 29.4

0.491

AST (IU/L)

66.5 ± 28.3

63.1 ± 22.0

0.563

ALT (IU/L)

79.2 ± 45.4

74.7 ± 41.5

0.398

ALT (IU/L)

88.0 ± 67.4

63.0 ± 26.1

0.083

γGT (IU/L)

112.0 ± 80.4

115.4 ± 95.7

0.713

γGT (IU/L)

232.8 ± 144.7

163.8 ± 102.3

0.023